NASDAQ:GENE

Genetic Technologies Stock Forecast, Price & News

$3.32
-0.03 (-0.90 %)
(As of 09/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.27
$3.39
50-Day Range
$2.98
$3.90
52-Week Range
$2.77
$8.18
Volume86,649 shs
Average Volume1.11 million shs
Market Capitalization$51.05 million
P/E RatioN/A
Dividend YieldN/A
Beta2.47
30 days | 90 days | 365 days | Advanced Chart
Receive GENE News and Ratings via Email

Sign-up to receive the latest news and ratings for Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter.


Genetic Technologies logo

About Genetic Technologies

Genetic Technologies Ltd. is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. It operates through the USA and Australia geographical segments. The firm's product BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

0.75 out of 5 stars

Medical Sector

1281st out of 1,352 stocks

Biological Products, Except Diagnostic Industry

186th out of 193 stocks

Analyst Opinion: 0.0Community Rank: 3.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Genetic Technologies (NASDAQ:GENE) Frequently Asked Questions

What stocks does MarketBeat like better than Genetic Technologies?

Wall Street analysts have given Genetic Technologies a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Genetic Technologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Genetic Technologies?

Genetic Technologies saw a increase in short interest in the month of July. As of July 30th, there was short interest totaling 1,060,000 shares, an increase of 27.6% from the July 15th total of 830,800 shares. Based on an average daily trading volume, of 658,100 shares, the days-to-cover ratio is presently 1.6 days.
View Genetic Technologies' Short Interest
.

How has Genetic Technologies' stock been impacted by COVID-19?

Genetic Technologies' stock was trading at $2.36 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GENE shares have increased by 40.7% and is now trading at $3.32.
View which stocks have been most impacted by COVID-19
.

Who are Genetic Technologies' key executives?

Genetic Technologies' management team includes the following people:
  • Simon Morriss, Chief Executive Officer
  • Stan Sack, Chief Operating Officer
  • Michael Tonroe, Chief Financial Officer & Secretary
  • Richard Allman, Chief Scientific Officer
  • Jerzy Muchnicki, Executive Director & Chief Medical Officer

Who are some of Genetic Technologies' key competitors?

What other stocks do shareholders of Genetic Technologies own?

What is Genetic Technologies' stock symbol?

Genetic Technologies trades on the NASDAQ under the ticker symbol "GENE."

Who are Genetic Technologies' major shareholders?

Genetic Technologies' stock is owned by a number of retail and institutional investors. Top institutional investors include Susquehanna International Group LLP (0.00%), Simplex Trading LLC (0.00%), Morgan Stanley (0.40%), Morgan Stanley (0.40%), Group One Trading L.P. (0.00%) and Susquehanna Fundamental Investments LLC (0.24%).

Which major investors are selling Genetic Technologies stock?

GENE stock was sold by a variety of institutional investors in the last quarter, including Susquehanna Fundamental Investments LLC, Citadel Advisors LLC, Goldman Sachs Group Inc., and Cutler Group LP.

Which major investors are buying Genetic Technologies stock?

GENE stock was acquired by a variety of institutional investors in the last quarter, including Simplex Trading LLC, Morgan Stanley, Morgan Stanley, Group One Trading L.P., Susquehanna International Group LLP, and Jump Financial LLC.

How do I buy shares of Genetic Technologies?

Shares of GENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genetic Technologies' stock price today?

One share of GENE stock can currently be purchased for approximately $3.32.

How much money does Genetic Technologies make?

Genetic Technologies has a market capitalization of $51.05 million and generates $90,000.00 in revenue each year.

When was Genetic Technologies founded?

Genetic Technologies was founded in 1989.

What is Genetic Technologies' official website?

The official website for Genetic Technologies is www.gtgcorporate.com.

Where are Genetic Technologies' headquarters?

Genetic Technologies is headquartered at 60-66 HANOVER STREET, FITZROY C3, 3065.

How can I contact Genetic Technologies?

Genetic Technologies' mailing address is 60-66 HANOVER STREET, FITZROY C3, 3065. The biotechnology company can be reached via phone at (138) 412-7000 or via email at [email protected]


This page was last updated on 9/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.